Ceramides (Oral) — The Skin Barrier Restorer

Ceramides are the dominant lipid class in the stratum corneum, forming the lamellar bilayer structures that restrict water evaporation and prevent transdermal penetration of allergens and pathogens. With age and environmental stress, ceramide synthesis declines, disrupting barrier integrity and increasing TEWL. Orally ingested plant ceramides (glucosylceramides) are hydrolysed in the small intestine by glucocerebrosidase to ceramide and sphingosine, which are absorbed and transported to the skin via the lymphatic system. Once in keratinocytes, they are re-glycosylated and incorporated into lamellar bodies, ultimately secreted into the intercellular spaces of the stratum corneum. This systemic delivery pathway bypasses the limitations of topical application and ensures ceramide replenishment throughout the entire skin surface.

A 2017 double-blind, placebo-controlled trial published in Nutrients demonstrated that 30 mg/day of wheat-derived ceramides (Lipowheat) for 90 days significantly improved skin hydration (+35%), reduced TEWL (-28%), and improved skin elasticity compared to placebo in women with dry skin. A 2019 study in the Journal of Cosmetic Dermatology confirmed similar findings with konjac-derived ceramides at 40 mg/day over 12 weeks, with particular benefits in facial skin smoothness and reduction of fine lines. Bioavailability studies using radiolabelled glucosylceramides confirm systemic absorption and skin-targeted distribution.

Clinically studied doses range from 30–40 mg/day of plant-derived ceramide complex (standardised to glucosylceramide content). Lipowheat (wheat-derived) and ceramosides (konjac-derived) are the two most clinically validated branded ingredients. Effects are typically observed after 8–12 weeks of consistent daily supplementation. Best taken with a meal containing dietary fat to optimise lymphatic absorption.

Oral ceramides from wheat and konjac have an excellent safety profile in clinical trials up to 90 days. Individuals with wheat allergy or coeliac disease should use konjac-derived ceramides rather than wheat-derived formulations. No significant drug interactions have been identified. The compound is not systemically active in the same manner as pharmaceutical sphingolipid modulators, so systemic sphingolipid pathway disruption is not a concern at supplemental doses.

Key Papers